web analytics
1.3 C
Munich
Sunday, November 27, 2022

Rushnet Inc (OTCMKTS: RSHN) Powerful Run Northbound as CO Reports Record Revenues, Cancels Reverse Stock Split & Looks Towards Major Acquistion

Rushnet Inc (OTCMKTS: RSHN) is making a powerful run northbound after the Company reported in an update that the reverse split has been cancelled and the Company was working on a major acquisition to help grow the business to $50 million in revenue in three years. RSHN is already a revenues powerhouse recently reporting $5,893,984 in revenues during fiscal year 2021 more than double 2020 revenues. The last time we reported on RSHN in December the Company was the subject of a 6 Part interview series to be conducted by FMW Media’s New to The Street/ Newsmax that will be carried by a number of nationwide media outlets including Fox Business, Bloomberg Network, Newsmax, KRON, RNN, and potentially other outlets. The reach of these networks is in excess of over 300 million homes. RSHN is under accumulation and volume has picked up substantially as the stock makes a move to the upside. RSHN did make a solid move last year rocketing to $0.0249 highs in June.

The rise in RSHN revenues comes from its fast-growing operating subsidiaries heliosDX and Grandeza Healthcare. heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The Company is contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Management is looking to spin off heliosDX as a standalone Company with new shares in the Company distributed to current shareholders. Grandeza Healthcare is a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals.  

Rushnet Inc (OTCMKTS: RSHN) operating out of Orange Park, Florida has transformed over the past year into a revenue powerhouse with the acquisition of heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. Always staying ahead of the curve, by continually investing in its infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. The Company excels in patient and client care through physician designed panels that aid in testing compliance and reporting education. heliosDX as the first step to bring value to shareholders. The has company progressed in the last few months and plans future acquisitions to bolster company and shareholder value.  

Microcapdaily has been reporting on Rushnet for years and in our last article on the Company back in March we stated: “Rushnet Inc has been around for years selling edibles and beverage-based company with stand-alone products, including most enhanced with CBD. Recently they acquired HeliosDx and Chattahoochee Labs which has been around since 2006 and has generated well over 6 million dollars in revenue in 2021.This year we take on our third mass spectrometer, the powerful Absciex 4500, which will allow us to serve the massive needs of our clientele, which has been under strain. With the procurement of a new QuantStudio 12x we now have the ability to test 1500 Covid19 patients per day. With infectious disease testing validations being completed next week, we will be able to better serve clients all over by creating more robust testing menus and quicker turnaround time for Covid19, UTI, and RPP testing. Furthermore, with the assumption of our Ion S5 GeneStudio NGS testing equipment, we are poised for the huge genetics market that is so underserved.” 

According to a recent update from the Company, the Rushnet, Inc. of the past is long gone. However, remnants of its historical dealings still cling to the business that have posed challenges to current management as it navigates the public sector in pursuit of the long-term goals that we’ve set for the current Rushnet. Today, we have a completely new face, new management and new goals within the National Diagnostics Laboratory and the Healthcare Billing and Coding space which is operating today as heliosDX and Grandeza Healthcare. The services and objectives of today are completely different and have an ultimate goal of continuing the enhancement of shareholder value. As in life, a business can be presented with various paths to choose in order to stay the course and achieve its ultimate long-term vision. The company’s (heliosDX and Grandeza Healthcare) goals have not changed: grow the business to $50 million in revenue in three years and thereby increase shareholder value. The company has not wavered from this target and aims to accomplish this vision. The main primary target on this long-term path has been to acquire another toxicology laboratory that we know will greatly benefit the business and its shareholders. 

  • As a result of cancelling the rs new opportunities have opened up for RSHN including: 
  • Can move forward with the Acquisition 
  • Can move forward with the split off of heliosDX to pursue up list of heliosDX, resulting in a dividend to RushNet shareholders instead of a consolidation 
  • Provide potential share conversions 
  • Can reduce Rushnet structure through other means 
  • Can explore other possible shareholder incentives to benefit the shareholders and company in the long run 

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RSHN

heliosDX,a subsidairy of RSHN is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. We intend to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In management’s opinion, following such best practices are intended to allow heliosDX to provide physicians fast and accurate reporting, meeting, and exceeding industry benchmarks. It is the company’s goal to excel in patient and client care through physician designed panels that aid in testing compliance and reporting education. 

Grandeza Healthcare, a subsidiary of RSHN is a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals. In addition to billing, we provide Revenue Cycle Management (RCM) for all clients, as well as customized consulting services. We are a rapidly growing company adding new services and value to further demonstrate our competitive advantage. 

heliosDX and Grandeza Healthcare are turning into revenue powerhouses for the Company which reported $5,893,984 in revenues during fiscal year 2021 most of it from Laboratory testing fees. This more than doubles total 2021 revenues of  $2,787,759. RSHN long term vision remains clear; the company’s (heliosDX and Grandeza Healthcare) goals have not changed: grow the business to $50 million in revenue in three years. 

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $15,531,819 market valuation the Company has 8,174,641,795 shares outstanding. While RSHN debt load may seem like a lot, the Company has serious potential and is executing at every level. The Company’s heliosDX and Grandeza Healthcare have seen significant growth since they were acquired and were responsible for $5,893,984 in total revenues in 2021 up more than double from 2020. The stock got a boost after the Company reported in an update that the reverse split has been cancelled and the Company was working on a major acquisition to help grow the business to $50 million in revenue in three years. RSHN is currently under heavy accumulation and has legions of shareholders and a growing international following that are bidding the price higher in recent trading.  RSHN is under heavy accumulation and volume has picked up substantially as the stock looks to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.0249 and its blue skies ahead. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RSHN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.